113
Participants
Start Date
June 28, 2021
Primary Completion Date
May 22, 2023
Study Completion Date
May 29, 2024
Cemiplimab
Administered intravenously (IV) every three weeks (Q3W)
ISA101b
Administered by subcutaneous (SC) injection on day 1, day 29, and day 50
CHIREC Delta Hospital / Chirec Cancer Institute, Brussels
UZ Leuven, Leuven
Universitair Ziekenhuis Gent, Ghent
Hospital Doctor Josep Trueta - Institut Catala d'Oncologia (ICO), Girona
IRCCS-Istituto Europeo di Oncologia, Milan
Hospital Universitario La Paz, Madrid
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola
Arizona Oncology Associates, Tucson
Arizona Oncology Associates, Tucson
Regeneron Research Site, Orange
State Budgetary Healthcare Institution Clinical Oncology Dispensary 1 Of Healthcare Department Of Krasnodar Region, Krasnodar
Instituto Nacional de Cancer Jose Alencar Gomes da Silva ¿ INCA, Santo Cristo
Centro de Pesquisa em Oncologia - Uniao Brasileira de Educacao e Assistencia Hospital Sao Lucas da PUCRS, Porto Alegre
Centro De Novos Tratamentos Itajai, Itajaí
Fundacao Pio XII - Hospital de Cancer de Barretos, Barretos
Instituto COI de Pesquisa, Educacao e Gestao - COI Clinicas Barra Da Tijuca (COI Clinicas Oncologicas Integradas SA), Rio de Janeiro
Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome
Maastricht University Medical Center, Maastricht
University Medical Center Groningen, Groningen
Leiden Universitair Medisch Centrum (LUMC), Leiden
Radboudumc, Nijmegen
Seoul National University Hospital, Seoul
University of Ulsan College of Medicine - Asan Medical Center (AMC), Seoul
Gangnam Severance Hospital, Seoul
Korea University Guro Hospital, Seoul
Hospital Universitari Vall d'Hebron, Barcelona
Collaborators (1)
ISA Pharmaceuticals B.V.
INDUSTRY
Regeneron Pharmaceuticals
INDUSTRY